Vivian Fonseca

Professor

Tulane University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Vivian Fonseca is a faculty member at Tulane University in the United States. His research primarily focuses on diabetes management, including the cost-effectiveness of treatments, nephrolithiasis risks associated with diabetes medications, and the cardiovascular safety of testosterone therapy. His recent publications address the implications of pricing in healthcare and the impact of metabolic factors on overall health in individuals with type 2 diabetes.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Guillermo Umpierrez

Professor of Medicine

Emory University School of Medicine

UNITED STATES

View details

Lizheng Shi

UNITED STATES

View details

Wenxi Huang

University of Florida

UNITED STATES

View details

Piaopiao Li

University of Florida

UNITED STATES

View details

Cyrus Desouza

University of Nebraska Medical Center

UNITED STATES

View details

Rory J. McCrimmon

UNITED KINGDOM

View details

Debra Winberg

Assistant Professor

Georgetown University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vivian Fonseca

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity

Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

Long-Term Testosterone Shows Cardiovascular Safety in Men With Testosterone Deficiency in Electronic Health Records

Value-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act

Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes

Proteomic Signature of BMI and Risk of Type 2 Diabetes

Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early‐onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study

A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States

Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial

Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score

Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women

Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary

The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial

Collaborators (7)

Guillermo Umpierrez

Lizheng Shi

Wenxi Huang

Piaopiao Li

Cyrus Desouza

Rory J. McCrimmon

Debra Winberg

Make your next move.

Vivian Fonseca

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity

Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

Long-Term Testosterone Shows Cardiovascular Safety in Men With Testosterone Deficiency in Electronic Health Records

Value-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act

Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes

Proteomic Signature of BMI and Risk of Type 2 Diabetes

Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early‐onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study

A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States

Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial

Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score

Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women

Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (&gt;8 Years): Executive Summary

The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial

Collaborators (7)

Guillermo Umpierrez

Lizheng Shi

Wenxi Huang

Piaopiao Li

Cyrus Desouza

Rory J. McCrimmon

Debra Winberg

Make your next move.

Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary